Constellation Pharmaceuticals, Inc.
Methods of treating myeloproliferative disorders

Abstract:

The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-y- l)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.